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INTRODUCTION: In elderly patients with acute myocardial infarction, very little is known about the role of surgical myocardial 
revascularization and percutaneous coronary intervention (invasive therapies - IT), especially in the context of long-term outcomes 
after hospital discharge.
METHODS: We analyzed 1588 patients with MI who had been included prospectively in a databank and followed for up to 7.5 
years. In this population, 548 patients were ≥70 years old (elderly group - EG), and 1040 were <70 years of age (younger group - 
YG); 1088 underwent IT during hospitalization, and the remaining 500 were treated medically (conservative therapy - CT). Patients 
were monitored either by visit or by phone at least once a year. A standard questionnaire was administered to all patients. The 
impact of IT was analyzed with both non-adjusted and adjusted models.
RESULTS: By the end of the follow-up period, the survival rates for the IT and CT groups were, respectively, 71.9% versus 47.2% 
in the global population (hazard ratio=0.55, P<0.001), 81.5% versus 66.6% in the YG (hazard ratio=0.68, P=0.018) and 48.8% 
versus 20.3% in the EG (hazard ratio=0.58, P<0.001). In the adjusted models, the hazard ratios were 0.62 (P<0.001) in the global 
population, 0.74 in the YG (P=0.073) and 0.64 (P=0.001) in the EG. 
CONCLUSION: Long-term follow-up of patients with myocardial infarction revealed that IT during the in-hospital phase was at 
least as effective in elderly patients as in younger patients.
KEYWORDS: Myocardial infarction; Long-term outcome; Elderly population; Coronary artery bypass surgery; Percutaneous 
coronary intervention.
INTRODUCTION
An increase in the life expectancy of patients with 
coronary artery disease (CAD) over the last few decades has 
led to an increase in the average age of patients hospitalized 
for acute myocardial infarction (MI). In the USA, about 
82% of patients who die of CAD are aged 65 or older.1 On 
the other hand, despite recent advances,2-6 it is well known 
that both the morbidity and mortality of CAD patients 
subjected to invasive therapies (ITs – coronary artery bypass 
surgery or percutaneous coronary intervention) increase 
with age, and that pre-intervention MI is an independent 
risk factor for mortality.7 Despite certain data from clinical 
trials suggesting a greater benefit of IT in elderly patients 
with acute coronary syndromes,8;9 the applicability of 
findings from trials that enrolled predominantly younger 
patients to an older and generally less healthy population is 
questionable.10
Specifically in the context of MI, it has been 
demonstrated that IT utilization is influenced by racial 
and socioeconomic factors,11;12 and that IT is underused 
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in the elderly population.13 Likely reasons for this 
include practitioner concerns about the increased risk of 
complications,14 patient heterogeneity, atypical presentation, 
and limited representation in clinical trials.15 However, 
very few published studies have addressed the impact of 
IT on long-term outcome after MI,16;17 with no data, to our 
knowledge14;15, specifically addressing the case of elderly 
patients. Therefore, the main objective of this study was to 
analyze, in patients with acute myocardial infarction, the 
impact of IT on long-term outcome, with a special focus on 
the elderly.
METHODS
From an initial population of 1623 patients with MI 
included prospectively in a dedicated databank between 
01/1998 and 01/2005, we analyzed 1588 patients [mean 
age 63.26 + 12.9 y (range 10 to 98 y), 71.7% men] who 
were followed for up to 7.5 years (mean survival time=5.65 
years). Thirty-five patients (20 in the invasive and 15 in the 
conservative group, 2.2% from the initial population) were 
lost to follow-up and excluded from the present report. In the 
invasive group (1086 pts, since we received only vital signs 
data in 2 cases), after the index hospitalization 75 pts (6.9%) 
were submitted to percutaneous coronary intervention (PCI) 
and 34 (3.13%) to coronary artery bypass surgery (CABG). 
In the conservative group (499 pts, since in one case we 
received only vital signs data), after the index hospitalization 
29 (5.8%) were submitted to PCI and 4.4% to CABG. 
In the population we studied, 548 patients were >70 
years old (elderly group – EG), and the remaining 1040 
patients were <70 years old (younger group – YG). In 
addition, of the 1588 patients, 1088 underwent IT during 
hospitalization (519 non-primary PCI, 344 primary PCI, 272 
CABG, 47 both therapeutic modalities – none was submitted 
to the 3 procedures). The remaining 500 patients comprised 
the group that did not undergo IT during hospitalization 
(conservative group, CT). In the elderly population, 334 
(60.9%) patients underwent IT and 214 (39.1%) patients 
underwent CT. Within the YG, 754 (72.5%) underwent IT 
and 286 (27.5%) underwent CT. 
Follow-up was performed by personal contact or 
by phone at least once a year, and patients submitted a 
questionnaire with information about their outcome after 
hospital discharge. Definitions and therapies utilized during 
the hospitalization period followed internal institutional 
guidelines, based on recommendations from the Brazilian, 
European and North-American Societies of Cardiology. In 
the long-run, patients were followed by his/her physician, 
meaning that no standardized therapeutic routine of follow-
up was implemented.
Statistical analyses: Characteristics of the global 
population, EG and YG groups were compared using Pearson 
chi-square tests or Fisher exact tests as appropriate. Kaplan-
Meier estimates of survival in the global population, EG and 
YG were determined and statistically evaluated using the 
log-rank test. Interaction tests between age (as a continuous 
variable) and therapeutic strategy with regard to mortality 
were developed for the whole population, the EG and the 
YG. The Stepwise Cox proportional hazards regression 
model was used in the adjusted models. The thresholds for 
each step were 0.05 for entry and 0.10 for removal; all-cause 
mortality was the dependent variable, and the candidates 
for independent predictors were: history of MI, previous 
percutaneous coronary intervention or coronary artery 
bypass graft, heart failure, diabetes mellitus, stroke, arterial 
hypertension, hypercholesterolemia, smoking, family history 
of coronary artery disease, type of MI (ST elevation or non-
ST elevation), MI location (anterior wall or other), gender, 
conservative/invasive treatment during hospitalization and 
fibrinolytic utilization. SPSS 13.0 software was utilized for 
the calculations.
RESULTS
The number of patients from the study population 
submitted to coronary angiography was 1417 (89.2%), with 
452 (82.5%) of these from the EG and 965 (92.8%) from 
the YG (P<0.001, 95% CI of the difference 13.5 to 7.08). 
Invasive therapies were utilized in 334 (60.9%) patients from 
the EG and 754 (72.5%) patients from the YG (P<0.001, 
95% CI 6.79 to 16.4). 
Univariate comparisons between the conservative and 
invasive groups in the global population, in the elderly 
group and in the younger group are listed in Tables 1, 2 and 
3, respectively. As can be seen, CT patients exhibited higher 
incidences of previous MI, revascularization surgery and 
heart failure, and IT patients were more likely to be male, 
smokers, and to have hypercholesterolemia, ST-elevation MI, 
anterior wall MI and a family history of CAD.
Figures 1, 2 and 3 show the estimated survival rates 
of all the patients, the YG patients and the EG patients, 
respectively. As can be noticed, patients who underwent 
IT during hospitalization exhibited better outcomes than 
those treated medically. The hazard-ratio and P-values seem 
to suggest a more impressive benefit in the older group, 
but no formal interaction between age and IT benefit in 
the whole population was observed. Moreover, the curves 
diverge earlier in the elderly group - suggesting an earlier 
benefit in these patients. Figure 4 shows the estimated 
mean survival times of the CT and IT groups for each of 
the analyzed populations. Including in-hospital deaths, the 
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CT and IT survival times in the global population were, 
respectively: 1819 (95% CI 1710 to 1928) vs. 2188 (95% 
CI 2121 to 2254) days; in the YG they were 2214 (95% CI 
2093 to 2335) vs. 2378 (95% CI 2310 to 2446) days; and 
in the EG they were 1267 (95% CI 1101 to 1434) vs. 1753 
(95% CI 1612 to 1894) days. Excluding in-hospital deaths, 
the CT and IT survival times in the global population were, 
respectively: 2083 (95% CI 1979 to 2188) vs. 2420 (95% CI 
2363 to 2471) days; in the YG they were 2349 (95% CI 2239 
to 2460) vs. 2506 (95% CI 2448 to 2565) days; and in the 
EG they were 1620 (95% CI 1437 to 1803) vs. 2181 (95% 
CI 2046 to 2315) days. Testing for interactions between the 
effects of age and treatment strategy on death rates yielded 
a P-value of 0.783 for the whole population, 0.125 for the 
younger group, and 0.893 for the elderly group.
The average durations of the index hospitalization stays 
were 15.1 + 14.7 days for the EG and 12.5 + 13.3 days 
for the YG (P=0.001, 95% CI 1.13 to 4.15). For patients 
submitted to IT, there were no significant survival differences 
between primary angioplasty, non-primary angioplasty and 
Table 1 - Comparison of conservative and invasive therapy in the global population
Variables Cons. Group (N=500) Inv. Group (N=1088) P-value Odds-ratio (95% CI)
Hx MI (%) 33.4 26.7 0.006 0.72 (0.58 to 0.91)
Hx PCI (%) 11.6 11.6 0.991 1.0 (0.72 to 1.39)
Hx CABG (%) 17.6 11.8 0.002 0.62 (0.46 to 0.84)
Hx HF (%) 12.0 5.2 <0.001 0.41 (0.28 to 0.60)
Hx DM (%) 26.4 27.7 0.599 1.07 (0.84 to 1.36)
Hx stroke (%) 3.4 3.7 0.783 1.08 (0.61 to 1.93)
Hx hypertension (%) 67.8 65.4 0.356 0.90 (0.72 to 1.13)
Family Hx of CAD (%) 21.2 29.0 0.001 1.52 (1.18 to 1.96)
Hx hypercholesterolemia (%) 39.2 49.3 <0.001 1.51 (1.21 to 1.87)
Hx smoking (%) 23.6 31.0 0.003 1.45 (1.14 to 1.85)
ST-elevation MI (%) 39.8 62.7 <0.001 2.54 (2.04 to 3.17)
Anterior MI (%) 37.0 44.9 0.003 1.39 (1.12 to 1.73)
Fibrinolytic (%) 20.0 21.5 0.494 1.09 (0.84 to 1.42)
Men (%) 66.4 74.1 0.002 1.45 (1.15 to 1.82)
Cons.=conservative; Inv.=invasive; CI=confidence interval; Hx=history of; MI=myocardial infarction; PCI=percutaneous coronary intervention; 
CABG=coronary artery bypass graft; HF=heart failure; DM=diabetes mellitus; CAD=coronary artery disease.
Table 2 - Comparison of conservative and invasive therapy in elderly patients
Variables Cons. Group (N=214) Inv. Group (N=334) P-value Odds-ratio (95% CI)
Hx MI (%) 39.3 28.4 0.008 0.62 (0.43 to 0.88)
Hx PCI (%) 12.1 12.3 0.965 1.01 (0.60 to 1.71)
Hx CABG (%) 19.6 17.4 0.504 0.86 (0.55 to 1.34)
Hx HF (%) 17.8 7.5 <0.001 0.38 (0.22 to 0.64)
Hx DM (%) 29.4 29.9 0.900 1.02 (0.70 to 1.49)
Hx stroke (%) 4.2 5.7 0.442 1.37 (0.61 to 3.09)
Hx hypertension (%) 74.8 65.6 0.023 0.64 (0.44 to 0.94)
Family Hx CAD (%) 14.0 20.1 0.071 1.54 (0.96 to 2.46)
Hx hypercholesterolemia (%) 37.4 43.4 0.162 1.28 (0.90 to 1.83)
Hx smoking (%) 8.9 11.4 0.350 1.32 (0.74 to 2.35)
ST-elevation MI (%) 34.7 57.5 <0.001 2.65 (1.85 to 3.78)
Anterior MI (%) 36.4 46.4 0.021 1.51 (1.06 to 2.15)
Fibrinolytic (%) 11.7 12.6 0.756 1.09 (0.64 to 1.84)
Men (%) 60.7 63.2 0.568 1.11 (0.78 to 1.58)
Legend as for Table 1
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Table 4 - Non-adjusted and adjusted hazard ratios for invasive and conservative treatment in the global population, and in 
younger and elderly groups
Groups Non-adjusted HR 95% CI P-value Adjusted HR 95% CI P-value
Global 0.55 0.45-0.67 <0.001 0.62 0.51-0.77 <0.001
Younger 0.68 0.49-0.94 0.018 0.74 0.53-1.03 0.073
Elderly 0.58 0.45-0.75 <0.001 0.64 0.49-0.83 0.001
Table 3 - Comparison of conservative and invasive therapy in younger patients
Variables Cons. Group (N=286) Inv. Group (N=754) P-value Odds-ratio (95% CI)
Hx MI (%) 29.0 25.9 0.304 0.85 (0.63 to 1.15)
Hx PCI (%) 11.2 11.3 0.969 1.0 (0.65 to 1.55)
Hx CABG (%) 16.1 9.3 0.002 0.53 (0.36 to 0.78)
Hx HF (%) 7.7 4.2 0.025 0.53 (0.30 to 0.93)
Hx DM (%) 24.1 26.7 0.406 1.14 (0.83 to 1.57)
Hx stroke (%) 2.8 2.8 0.992 1.0 (0.47 to 2.27)
Hx hypertension (%) 62.2 65.4 0.400 1.13 (0.85 to 1.50)
Family Hx CAD (%) 26.6 32.9 0.049 1.35 (1.00 to 1.83)
Hx hypercholesterolemia (%) 40.6 51.9 0.001 1.58 (1.20 to 2.08)
Hx smoking (%) 34.6 39.7 0.135 1.24 (0.93 to 1.65)
ST-elevation MI (%) 43.9 64.6 <0.001 2.33 (1.76 to 3.10)
Anterior MI (%) 37.4 44.3 0.045 1.33 (1.01 to 1.76)
Fibrinolytic (%) 26.2 25.5 0.802 1.96 (0.71 to 1.31)
Men (%) 70.6 78.9 0.005 1.56 (1.14 to 2.12)
Legend as for Table 1
Figure 1 - Cumulative survival rates for the global population (Hazard ratio 
0.55, P<0.001)
Figure 2 - Cumulative survival rates for the younger population (Hazard 
ratio 0.68, P=0.018)
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surgical revascularization; the estimated mean survival times 
were, respectively, 1476 (95% CI 1245 to 1706) days, 1795 
(95% CI 1590 to 2000) days and 1833 (95% CI 1566 to 
2100) days for the EG (P=0.160), and 2238 (95% CI 2099 
to 2378) days, 2392 (95% CI 2296 to 2488) days and 2399 
(95% CI 2310 to 2446) days for the YG (P=0.595). In the 
long run, the outcomes for patients with ST-elevation and 
non-ST-elevation MI were similar: for the EG, the estimated 
mean survival times were, respectively, 1711 (95% CI 1526 
to 1897) vs. 1811 (95% CI 1592 to 2030) days for patients 
submitted to IT (P=0.373) and 1254 (95% CI 990 to 1518) 
vs. 1265 (95% CI 1047 to 1483) days for those treated 
conservatively (P=0.946); for the YG, the figures were 2389 
(95% CI 2307 to 2471) vs. 2354 (95% CI 2235 to 2474) 
days for patients submitted to IT (P=0.757) and 2200 (95% 
CI 2020 to 2381) vs. 2168 (95% CI 1992 to 2344) days for 
those treated conservatively (P=0.540). 
In the adjusted models, IT correlated significantly, 
independently and inversely with long-term mortality in 
the elderly group (hazard ratio=0.64, P=0.001), but the 
hazard ratio obtained for the YG did not reach statistical 
significance (hazard ratio=0.74, P=0.073), as shown in 
Table 4. Other variables that correlated significantly and 
independently with mortality in the adjusted models were: 
in the global population, fibrinolytic utilization (HR=0.62, 
P=0.001); previous history of stroke (HR=2.06, P<0.001), 
hypercholesterolemia (HR=0.60, P<0.001), diabetes 
(HR=1.38, P=0.003), relatives with CAD (HR=0.67, 
P=0.003), smoking (HR=0.71, P=0.009), MI (HR=1.32, 
P=0.018) and heart failure (HR=2.28, P<0.001); in the YG, 
history of stroke (HR=2.12, P=0.017), hypercholesterolemia 
(HR=0.68, P=0.019), diabetes (HR=1.83, P<0.001), MI 
(HR=1.49, P=0.022), and heart failure (HR=3.38, P<0.001); 
and in the EG, history of angioplasty (HR=0.51, P=0.007), 
stroke (HR=2.45, P=0.001), hypercholesterolemia (HR=0.59, 
P<0.001), and heart failure (HR=1.73, P=0.004). 
In our institution, especially during more recent years, 
patients with ST-elevation MI receive primary PCI within 
12 hours of evolution on a routine basis. Therefore, for this 
subset, the conservative approach was almost never applied 
in practice. Because of this, adjusted models were developed 
excluding these patients, and showed that the IT group 
continued to fare significantly better than the conservative 
group: for the global population, the adjusted hazard ratio 
was 0.58 (P<0.001), for the EG it was 0.50 (P<0.001), and 
for the YG it was 0.70 (P=0.056). 
In order to avoid a possible early survival bias (i.e., 
patients have to live long enough to undergo an invasive 
procedure, causing IT to become a marker for early survival), 
Kaplan-Meier curves were constructed excluding in-hospital 
deaths. At the end of the follow-up, the following survival 
rates were obtained: in the global population (n=1417), 
54.4% + 5.3 and 79.9% + 2.2 respectively for the CT 
(n=435) and IT (n=982) groups (HR=0.45, P<0.001); in 
the EG (n=433), 26.3% + 8.9 and 61.5%+ 8.6 respectively 
for the CT (n=166) and IT (n=267) groups (HR=0.41, 
P<0.001); and in the YG (n=984), 71.0% + 5.3 and 86.1% + 
2.0 respectively for the CT (n=269) and IT (n=715) groups 
(HR=0.60, P=0.01). In the adjusted models, the following 
hazard ratios were obtained: for the global population, 0.50 
(P<0.001); for the EG, 0.44 (P<0.001); and for the YG, 0.63 
(P=0.024). Tests for interactions between the effects of age 
and treatment strategy on death rates showed P-values of 
0.714, 0.002 and 0.69 in the whole population, YG, and EG, 
respectively.
Figure 3 - Cumulative survival rates for the elderly population (Hazard 
ratio 0.58, P<0.001)
Figure 4 - Estimated mean survival time (days) including (incl.) or exclud-
ing (excl.) in-hospital deaths (HD) for the global population, younger group 
(YG) and elderly group (EG). The 95% confidence intervals for each group 
are listed in the text.
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DISCUSSION
The underutilization of invasive therapies in the 
elderly: Many studies have unequivocally shown that 
invasive therapies are underutilized in the elderly.13 MI 
patients who are older appear to wait the longest before 
seeking medical attention.18 Furthermore, IT is associated 
with higher morbidity and mortality rates in this population 
than in younger people, leading to longer hospital stays, 
and likely influencing the assisting physician to be more 
conservative with these patients. In our study population 
these tendencies were confirmed: IT was utilized less 
in older patients (60.9% and 72.5% in the EG and YG, 
respectively), the long-term survival rates were 48.9% and 
81.5%, respectively, and the hospitalization stays were, 
respectively, 15.1 and 12.5 days. In fact, some authors have 
proposed a convalescence cardiac unit for older patients 
as a transitional facility from hospital to home,19 and the 
optimal rate of invasive therapies is a frequent topic of 
discussion.20 
Differences between the elderly and younger groups: 
The data in Table 1 indicate that, in the global population, 
certain variables had different incidence rates in the IT and 
CT groups. These included previous heart failure (smaller 
incidence in the IT group) and ST-elevation MI and anterior 
MI location (higher incidences in the IT group). However, 
the variables associated with the IT and CT groups differed 
somewhat when the younger (Table 3) and older (Table 2) 
patients were considered separately. Arterial hypertension 
and previous MI were more frequent in elderly IT patients 
than in elderly CT patients, while the incidence rates 
of these variables were similar between the younger IT 
and CT patients. However, in younger patients (but not 
in older patients) there were different incidence rates of 
previous revascularization surgery, relatives with CAD and 
hypercholesterolemia in the IT and CT groups. There was 
a higher incidence of males in the IT group only among 
younger patients, and this was likely due to the higher 
proportion of women with MI in the elderly population.1
The role of IT in elderly and younger patients: In 
the TACTICS-TIMI 18 study that analyzed 2220 patients 
with non-ST elevation ACS, the significant benefit in the 
composite endpoint (6-month mortality, nonfatal MI, 
rehospitalization, stroke, and hemorrhagic complications) 
demonstrated for the invasive approach was restricted to 
elderly patients (65 years-old or older), while the invasive 
and conservative approaches yielded similar results in the 
younger population.8 It is important to note, in that study, 
that the mortality rates were similar for the invasive and 
conservative groups (1.8% and 1.7% respectively for 
younger people, 5.3% and 5.9% respectively for the elderly 
population). Moreover, as pointed out by the authors, the 
generalizability of the results for elderly patients without the 
excluded comorbid conditions remain unknown. Probably 
the most feared complication in elderly people is bleeding. 
In the GRACE Registry, the investigators observed that 10% 
of all hospital deaths were related to major bleeding, and 
the incidence of this complication was clearly correlated 
with age.21 On the other hand, the CRUSADE Registry 
demonstrated that, in patients over 89 years old, the higher 
risk of bleeding related to invasive therapies is outweighed 
by the obtained benefit.22 Recently it has been shown that 
people 80 years and older who receive drug-eluting stents are 
more likely to die in the year following stent implantation 
than younger patients, but they are no more likely to require 
repeat revascularization procedures. After adjusting for age 
and sex, the life expectancy of the DES-treated octogenarians 
was similar to that of the general population, despite the 
fact that older subjects tended to be sicker at the time of 
stenting.23
On the other hand, primary PCI was shown to be highly 
effective in patients with ST-elevation MI.24 In our study, 
which included MI patients both with and without ST 
elevation, the benefit of invasive therapies was maintained 
even when patients submitted to primary PCI were excluded 
from the analyses. Moreover, taking into account long-term 
survival and excluding in-hospital deaths, a significant 
correlation between age and invasive therapy was found 
in the YG but not in the EG, suggesting that the impact of 
age on long-term results is more pronounced in younger 
patients.
Limitations of the study: The main limitation of 
the study is the fact that patients were not allocated to 
IT and CT groups in a randomized manner. In addition, 
the reasons for not submitting certain patients to invasive 
therapies were not retrievable from the databank. On the 
other hand, this study accurately depicts treatment realities 
in a high-volume, tertiary cardiology hospital. Moreover, 
there is little evidence that estimates of treatment effects in 
observational studies are either consistently larger than or 
qualitatively different from those obtained in randomized 
controlled trials.25 Another limitation is that characteristics 
specific to our hospital and its patient population may limit 
how generalizable our results are to hospitals and regions 
dissimilar to ours. 11;12;26 A third possible limitation is the fact 
that the analyzed population was not treated with the same 
protocol after hospital discharge, since this treatment was 
left to the discretion of the attending physician. Moreover, 
a transdisciplinary approach to the follow-up could improve 
the general results.27 However, since this approach is widely 
utilized, even in randomized trials,28 we believe that this fact 
did not confound our results. 
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In conclusion, in the long-term after myocardial 
infarction, invasive therapies utilized during the in-hospital 
phase are at least as efficacious in elderly patients as in 
younger patients. 
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